Implantable cardioverter-defibrillators (ICDs) are one of the few interventions where we can be reasonably confident that a patient did or did not benefit from the treatment. If one is to benefit from an ICD, then the person must survive long enough to have an arrhythmic event and receive therapy from the device. Thus, the patients who benefit the most are those with a high rate of arrhythmic death and a low rate of nonarrhythmic death. Indeed the enrollment criteria for clinical trials of ICDs were designed to optimize these 2 rates. Accordingly, the patients enrolled in the primary prevention ICD trials were much younger and had less comorbidity than the community heart failure population.\(^1\)

On the basis of trial results, we now have guidelines for ICDs that limit them to patients with an ejection fraction below 35% if symptomatic (New York Heart Association Class II or III) or <30% if asymptomatic (New York Heart Association Class I) and expected survival of at least one year.\(^2\) However, the clinician is frequently confronted with a patient who meets the primary prevention ICD criteria yet has other characteristics (advanced age or multiple comorbidities) that create legitimate concern that the patient will not benefit from the device. Payers, policy makers, and society warn that even if there is a benefit in these patients, it may be too small to justify the cost. In other words, they question whether an ICD has value in the elderly and those with multiple comorbidities. Although no threshold for value has been widely accepted, many consider a cost per life year (or quality-adjusted life year) gained below $50 000 to $100 000 to be cost-effective. Past economic analyses of the populations enrolled in the ICD clinical trials were much younger and had less comorbidity than the community heart failure population.\(^3\)

The opinions expressed in this article are not necessarily those of the editors or of the American Heart Association.

From the Veterans Affairs Palo Alto Health Care System (P.H.), Palo Alto, Calif; and the Stanford University School of Medicine (P.H., V.T.), Stanford, Calif.

Correspondence to Paul Heidenreich, MD, MS, 111C Cardiology, VA Palo Alto Health Care System, 3801 Miranda Ave, Palo Alto, CA 94304. E-mail heiden@stanford.edu

(Circ Cardiovasc Qual Outcomes. 2009;2:6-8.)
© 2009 American Heart Association, Inc.

Circ Cardiovasc Qual Outcomes is available at http://circoutcomes.ahajournals.org
DOI: 10.1161/CIRCOUTCOMES.108.842369

Is Anyone Too Old for an Implantable Cardioverter-Defibrillator?

Paul A. Heidenreich, MD, MS; Vivian Tsai, MD

We can see from the Figure that one can be too healthy for an ICD. If the annual risk of death is less than 5%, then an ICD is very expensive for the gain in benefit (ie, not worth it). If total mortality is at least 5% per year, we then examine the ratio of arrhythmic to nonarrhythmic mortality. We see that if this ratio is at least 50:50 then ICDs have value even at extremely high mortality rates. Indeed, the model indicates that among patients with an expected median survival of less than 1 year (median 1 year mortality >50%) and currently excluded from receiving an ICD by guidelines) an ICD would still be of value if arrhythmic deaths were at least as likely as nonarrhythmic deaths.

But how can we predict who will and will not have an arrhythmic death? A recent study examined the relationship between arrhythmic death rate and age.\(^7\) Using an analysis of clinical trials of patients with heart failure or myocardial infarction Krahm found that arrhythmic and nonarrhythmic death rate both increase in absolute terms as one ages, with nonarrhythmic death rates increasing faster (Table). Using the Figure, we can estimate cost-effectiveness for the different age groups. First, we see that these estimates of value show a similar pattern to those by Chan et al. Both models agree that
ICDs for patients in their 70s appears to be a reasonable value, though we project that beyond 80 years of age that is less likely to be the case. Most of these patients in the >80 years group from the Krahn analysis (Table) were in their early 80s, and the value of an ICD in those 85 years and higher is likely to be much smaller.

Although age is clearly important, including other variables such as comorbidities may improve the estimates of arrhythmic death. The Seattle Heart Failure Model is a validated prediction tool of total mortality using clinical, laboratory, medication, and device variables. The model was used to predict cause of death (arrhythmic and pump failure or other) in a cohort of over 10,000 patients with heart failure from 6 clinical trials (Table). One year mortality for those with a score of 0 was less than 5% so ICDs are unlikely to be of value in these patients. Similarly, the ICDs do not appear to be a good value in the sickest patients who have a relatively low rate of arrhythmic death compared to nonarrhythmic death.

The purpose of this exercise was to show the importance of both total mortality and the ratio of arrhythmic to nonarrhythmic death in determining the value of an ICD. The estimates of cost-effectiveness for an individual patient will depend on many factors not considered here including preference for length and quality of life which has been shown to be highly variable and often changes markedly following an acute episode of heart failure.

What can we conclude from this? First, it is not simple to predict the relative rates of arrhythmic and nonarrhythmic causes of death with currently available data. Perhaps future markers will help. Second, as patients with heart failure age the increase in total mortality is somewhat offset by a slower increase in arrhythmic death rate making the

<table>
<thead>
<tr>
<th>Patient Group</th>
<th>Total Annual Mortality</th>
<th>Arrhythmic/Nonarrhythmic Ratio</th>
<th>Cost-Effectiveness, $/Quality-Adjusted Life Year*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, years†</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;50</td>
<td>11</td>
<td>1.1</td>
<td>$55,000</td>
</tr>
<tr>
<td>51–60</td>
<td>13</td>
<td>0.9</td>
<td>$60,000</td>
</tr>
<tr>
<td>61–70</td>
<td>18</td>
<td>0.65</td>
<td>$65,000</td>
</tr>
<tr>
<td>71–80</td>
<td>22</td>
<td>0.65</td>
<td>$65,000</td>
</tr>
<tr>
<td>&gt;80</td>
<td>25</td>
<td>0.34</td>
<td>$85,000</td>
</tr>
<tr>
<td>Seattle Heart Failure Model score‡</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0 (healthiest 38%)</td>
<td>4</td>
<td>4</td>
<td>$100,000</td>
</tr>
<tr>
<td>1 (41% of patients)</td>
<td>11</td>
<td>1.3</td>
<td>$50,000</td>
</tr>
<tr>
<td>2 (16% of patients)</td>
<td>24</td>
<td>0.72</td>
<td>$65,000</td>
</tr>
<tr>
<td>3 (3% of patients)</td>
<td>55</td>
<td>0.67</td>
<td>$85,000</td>
</tr>
<tr>
<td>4 (sickest 0.5%)</td>
<td>82</td>
<td>0.46</td>
<td>$150,000</td>
</tr>
</tbody>
</table>

*Cost effectiveness estimates from the Figure adapted from Am Heart J. 2002;144:440–448.
†Adapted from Am Heart J. 2004;147:837–840.
‡Adapted from Circulation. 2007;116:392–398.
cost-effectiveness of ICDs relatively stable until patients are into their mid 80s. Is there an age limit beyond which there is poor value from an ICD? Yes, but we will need additional well-designed outcome studies like Chan’s to determine what age this might be and to fill in the many other knowledge gaps not addressed by clinical trials.

Disclosures
Dr. Heidenreich has the following potential conflict of interest: Consultant to the ALTITUDE Clinical Science Initiative, Sponsored by Boston Scientific, less than $5000.

References

Key Words: editorials ▪ cost-benefit analysis ▪ defibrillation ▪ heart failure ▪ aged ▪ defibrillators ▪ implantable ▪ heart failure
Is Anyone Too Old for an Implantable Cardioverter-Defibrillator?
Paul A. Heidenreich and Vivian Tsai

Circ Cardiovasc Qual Outcomes. 2009;2:6-8
doi: 10.1161/CIRCOUTCOMES.108.842369

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://circoutcomes.ahajournals.org/content/2/1/6

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in Circulation: Cardiovascular Quality and Outcomes can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to Circulation: Cardiovascular Quality and Outcomes is online at:
http://circoutcomes.ahajournals.org//subscriptions/

Copyright © 2009 American Heart Association, Inc. All rights reserved.